All News
ACR 2018 - Day 4 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
In pts with #SystemicSclerosis, cardiac MRI with T1 mapping sequence revealed microscopic #MyocardialFibrosis in 53% of pts and was associated with #cardiovascular events (7 heart rhythm disorders, 2 heart failure, 1 unstable angina) Abstract2934 Dr.Terrier #ACR18 @RheumNow
Nicole Bitencourt NicoleBitencou5 ( View Tweet)
In #SystemicSclerosis, pts with esphageal erosions on EGD had a greater decline in FVC and progression of #ILD. Emphasizes role of micro-aspiration of gastric contents in #pathogenesis of #ILD in #scleroderma. Abstract 2936 Dr. Silvia Laura Bosello #ACR18 @RheumNow https://t.co/20hOAfS6rw
Nicole Bitencourt NicoleBitencou5 ( View Tweet)
Abstract 648 OptiRef self report questionnaire for early diagnosis of a spa - 19% had confirmed diagnosis vs 40% ref from Dr. Looks useful! #AS @rheumnow #ACR18
Philip Gardiner PhilipGardiner ( View Tweet)
Abst 651 Baraliakos MRI reports on SI joints in #AS differ between radiologists and rheumatologist: edema+erosion works best @RheumNow
Philip Gardiner PhilipGardiner ( View Tweet)
Abstr 837 Dr Colmegna: Should we use high dose Infleunza vaccine in #RA? Vaccines less effective in RA DB RCT low vs. High dose in 279 RApts. Showed sig. better immune response with high dose vaccine. #ACR18 @RheumNow
Philip Gardiner PhilipGardiner ( View Tweet)
#RA #ACR18 @RheumNow
Abstr 838: Anti-MDA5 pos DM-ILD has a poor prognosis. survival at 6mo 89% vs 33% with combo imsuppressive (Pred 1mg/kg/d tapering, IVCYC 500-1g/m2; Tacrolimus through 24 wk. 29 pts, historic controls. Hi risk of CMV activation #ACR18 #Myositis @rheumnow
Philip Gardiner PhilipGardiner ( View Tweet)
Plenary Abstract 839: Dr Schmukler Chicago. Can we use MDHAQ (multi-dimensional) to identify FM? 84% agreement with 2011 FMS questionnaire - so the answer is Yes! (But what is the ‘gold std’?) @RheumNow #FMS #ACR18
Philip Gardiner PhilipGardiner ( View Tweet)
Checkpoint inhibitors
explosion of papers in 2018
New and/or exacerbated arthritis, myositis, lupus, sarcoidosis, sjogrens, vasculitis
How to treat? - still unknown
Year in review - clinical
#ACR18 @RheumNow
D White WIRheum ( View Tweet)
Risk for infection with TNFi+MTX is NOT increased compared to triple DMARD Rx confirmed in large claims database of commercial insurance #ACR18 @RheumNow abst#218 https://t.co/p25QwUX3ZN
k dao KDAO2011 ( View Tweet)
Plenary session: High dose flu vaccine is safe and has better efficacy than standard flu vaccine in our adult RA patients abst#837 @RheumNow #ACR18 https://t.co/MzAB6mUnHS
k dao KDAO2011 ( View Tweet)
Q&A 'Over half the GCA patients had LVV+ on PET/CT' [note to self: need to insist on more PET/CT and push for Tocilizumb] #ACR18 @RheumNow #GCA
Philip Gardiner PhilipGardiner ( View Tweet)
Abst 884 Jeff Sparks. Predictors of ILD in #RA in 1281 patients: High disease activity, seropositivity - no surprises #ACR18 @RheumNow
Philip Gardiner PhilipGardiner ( View Tweet)
Personal observation here: over 25 years of practice I’ve seen disease activity fall and severe ILD become uncommon - but MTX use much more common. Time to rethink! #Acr18 #RA
Philip Gardiner PhilipGardiner ( View Tweet)
Abst 2977 Dr Werth Lenabasam - cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses - effective in reducing interferon beta and gamma in #Dermatomyositis skin biopsies #ACR18
Philip Gardiner PhilipGardiner ( View Tweet)
What’s in a name. Gout by any other name may be better treated. All hail Urate Crystal Arthritis#ACR18@RheumNow Abstract268 https://t.co/iGEENPJM85
William Shergy WilliamShergy ( View Tweet)
Lisa Sammaritano quoting a patient panel assisting in the development of Reproductive Guidelines for Rheumatology Patients. “My rheumatologist knows me better than my gynecologist.
William Shergy WilliamShergy ( View Tweet)
2789 Ph3 Apremilast for Behcet’s oral ulcers: significantly lower number of OU (P≤0.0015) &reduction in OU pain (P≤0.0035) vs PBO at wks 1-12. APR efficacy sustained at wk28: 62% pts achieved complete response of OU &70% relative
reduction in OU pain from BL. #acr18 @rheumnow
Olga Petryna DrPetryna ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)